<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">37140884</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1888</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>American journal of clinical dermatology</Title><ISOAbbreviation>Am J Clin Dermatol</ISOAbbreviation></Journal><ArticleTitle>Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.</ArticleTitle><Pagination><StartPage>521</StartPage><EndPage>540</EndPage><MedlinePgn>521-540</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40257-023-00774-8</ELocationID><Abstract><AbstractText>Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs; keratinocytes, cytotoxic T cells and plasmacytoid dendritic cells (pDCs) establish a self-perpetuating interplay between the innate and adaptive immune system that is pivotal for the pathogenesis of CLE. Therefore, treatment relies on avoidance of triggers and UV protection, topical therapies (glucocorticosteroids, calcineurin inhibitors) and rather unspecific immunosuppressive or immunomodulatory drugs. Yet, the advent of licensed targeted therapies for SLE might also open new perspectives in the management of CLE. The heterogeneity of CLE might be attributable to individual variables and we speculate that the prevailing inflammatory signature defined by either T cells, B cells, pDCs, a strong lesional type I interferon (IFN) response, or combinations of the above might be suitable to predict therapeutic response to targeted treatment. Therefore, pretherapeutic histological assessment of the inflammatory infiltrate could stratify patients with refractory CLE for T-cell-directed therapies (e.g. dapirolizumab pegol), B-cell-directed therapies (e.g. belimumab), pDC-directed therapies (e.g. litifilimab) or IFN-directed therapies (e.g. anifrolumab). Moreover, Janus kinase (JAK) and spleen tyrosine kinase (SYK) inhibitors might broaden the therapeutic armamentarium in the near future. A close interdisciplinary exchange with rheumatologists and nephrologists is mandatory for optimal treatment of lupus patients to define the best therapeutic strategy.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Niebel</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2069-0486</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Regensburg, 93053, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>de Vos</LastName><ForeName>Luka</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Bonn, 53127, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fetter</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Bonn, 53127, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xe4;gelmann</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0496-9041</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Bonn, 53127, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wenzel</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4744-5993</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Bonn, 53127, Bonn, Germany. Joerg.Wenzel@ukbonn.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>grant 2022-1A-08</GrantID><Agency>Medizinische Fakult&#xe4;t, Rheinische Friedrich-Wilhelms-Universit&#xe4;t Bonn</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Am J Clin Dermatol</MedlineTA><NlmUniqueID>100895290</NlmUniqueID><ISSNLinking>1175-0561</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008178" MajorTopicYN="Y">Lupus Erythematosus, Cutaneous</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015603" MajorTopicYN="N">Keratinocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Dennis Niebel has received speakers&#x2019; honoraria or travel expense reimbursements from Abbvie, Almirall, BMS, Boehringer Ingelheim,&#xa0;Eli Lilly, GlaxoSmithKline,&#xa0;Janssen-Cilag, Kyowa Kirin, LEO Pharma,&#xa0;L&#x2019;Oreal, MSD, Novartis, Pfizer,&#xa0;Sanofi-Aventis and UCB. Luke de Vos has received financial support (travel expenses) from Pierre Fabre. Christine Br&#xe4;gelmann has received financial support (travel grants) from L&#x2019;Or&#xe9;al, Novartis, ADF and EADV. Joerg Wenzel has received financial support (clinical studies, travel grants, speaker&#x2019;s fees) from GlaxoSmithKline, Novartis, Medac, Merck/Serono, Roche, Actelion, Pfizer, Spirig, ArrayBio, Biogen, and Incyte. Tanja Fetter declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>4</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>4</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37140884</ArticleId><ArticleId IdType="pmc">PMC10157137</ArticleId><ArticleId IdType="doi">10.1007/s40257-023-00774-8</ArticleId><ArticleId IdType="pii">10.1007/s40257-023-00774-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15:519&#x2013;532. doi: 10.1038/s41584-019-0272-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0272-0</ArticleId><ArticleId IdType="pubmed">31399711</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel J, Borucki R, Werth VP. An update on the pathogenesis of cutaneous lupus erythematosus and its role in clinical practice. Curr Rheumatol Rep. 2020;22:69. doi: 10.1007/s11926-020-00946-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-020-00946-z</ArticleId><ArticleId IdType="pubmed">32845411</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Wenzel J, Bijl M. Lupus erythematosus revisited. Semin Immunopathol. 2016;38:97&#x2013;112. doi: 10.1007/s00281-015-0550-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-015-0550-0</ArticleId><ArticleId IdType="pubmed">26637330</ArticleId></ArticleIdList></Reference><Reference><Citation>Udompanich S, Chanprapaph K, Suchonwanit P. Hair and scalp changes in cutaneous and systemic lupus erythematosus. Am J Clin Dermatol. 2018;19:679&#x2013;694. doi: 10.1007/s40257-018-0363-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40257-018-0363-8</ArticleId><ArticleId IdType="pubmed">29948959</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha KI, Wang DM, Miedema JR, Diaz LA. Cutaneous lupus erythematosus/lichen planus overlap syndrome. JAAD Case Rep. 2021;17:130&#x2013;151. doi: 10.1016/j.jdcr.2021.09.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2021.09.031</ArticleId><ArticleId IdType="pmc">PMC8556757</ArticleId><ArticleId IdType="pubmed">34754893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Wu H, Zhao M, Lu Q. New insights into the progression from cutaneous lupus to systemic lupus erythematosus. Expert Rev Clin Immunol. 2020;16:829&#x2013;837. doi: 10.1080/1744666X.2020.1805316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2020.1805316</ArticleId><ArticleId IdType="pubmed">32746644</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xf6;nhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164:1335&#x2013;1341. doi: 10.1111/j.1365-2133.2011.10272.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2011.10272.x</ArticleId><ArticleId IdType="pubmed">21574972</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AM, Lu G, Clifton SC, Ogunsanya ME, Chong BF. Influence of socio-demographic factors in patients with cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:916134. doi: 10.3389/fmed.2022.916134.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.916134</ArticleId><ArticleId IdType="pmc">PMC9311297</ArticleId><ArticleId IdType="pubmed">35899206</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Landmann A, Wenzel J. Advances in the treatment of cutaneous lupus erythematosus. Lupus. 2016;25:830&#x2013;837. doi: 10.1177/0961203316641771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316641771</ArticleId><ArticleId IdType="pubmed">27252259</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wu H, Zhou S, Zhao M, Lu Q. An Update on the Pathogenesis of Skin Damage in Lupus. Curr Rheumatol Rep. 2020;22:16. doi: 10.1007/s11926-020-00893-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-020-00893-9</ArticleId><ArticleId IdType="pubmed">32399815</ArticleId></ArticleIdList></Reference><Reference><Citation>Fetter T, Wenzel J. Cutaneous lupus erythematosus: The impact of self-amplifying innate and adaptive immune responses and future prospects of targeted therapies. Exp Dermatol. 2020;29:1123&#x2013;1132. doi: 10.1111/exd.14146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/exd.14146</ArticleId><ArticleId IdType="pubmed">32633821</ArticleId></ArticleIdList></Reference><Reference><Citation>Ker KJ, Teske NM, Feng R, Chong BF, Werth VP. Natural history of disease activity and damage in patients with cutaneous lupus erythematosus. J Am Acad Dermatol. 2018;79:1053&#x2013;1060.e3. doi: 10.1016/j.jaad.2018.06.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2018.06.040</ArticleId><ArticleId IdType="pmc">PMC6234101</ArticleId><ArticleId IdType="pubmed">29969701</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Sigges J, Biazar C, Ruland V, Patsinakidis N, Landmann A, et al. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol. 2014;171:571&#x2013;579. doi: 10.1111/bjd.13006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.13006</ArticleId><ArticleId IdType="pubmed">24673427</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. 2014;192:5459&#x2013;5468. doi: 10.4049/jimmunol.1002795.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002795</ArticleId><ArticleId IdType="pmc">PMC4083591</ArticleId><ArticleId IdType="pubmed">24907379</ArticleId></ArticleIdList></Reference><Reference><Citation>Stannard JN, Kahlenberg JM. Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus. Curr Opin Rheumatol. 2016;28:453&#x2013;459. doi: 10.1097/BOR.0000000000000308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000308</ArticleId><ArticleId IdType="pmc">PMC4965280</ArticleId><ArticleId IdType="pubmed">27270345</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Wenzel J, Weyd H. Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. Clin Rev Allergy Immunol. 2014;47:148&#x2013;162. doi: 10.1007/s12016-013-8403-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-013-8403-x</ArticleId><ArticleId IdType="pubmed">24420508</ArticleId></ArticleIdList></Reference><Reference><Citation>Niebel D, Novak N, Wilhelmi J, Ziob J, Wilsmann-Theis D, Bieber T, et al. Cutaneous adverse reactions to COVID-19 vaccines: insights from an immuno-dermatological perspective. Vaccines (Basel) 2021 doi: 10.3390/vaccines9090944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9090944</ArticleId><ArticleId IdType="pmc">PMC8470727</ArticleId><ArticleId IdType="pubmed">34579181</ArticleId></ArticleIdList></Reference><Reference><Citation>Fetter T, Braegelmann C, de Vos L, Wenzel J. Current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:915828. doi: 10.3389/fmed.2022.915828.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.915828</ArticleId><ArticleId IdType="pmc">PMC9196867</ArticleId><ArticleId IdType="pubmed">35712102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo MS. Monogenic Lupus. Curr Rheumatol Rep. 2016;18:71. doi: 10.1007/s11926-016-0621-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-016-0621-9</ArticleId><ArticleId IdType="pubmed">27812953</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HW, Barber G, Chong BF. The genetic landscape of cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:916011. doi: 10.3389/fmed.2022.916011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.916011</ArticleId><ArticleId IdType="pmc">PMC9201079</ArticleId><ArticleId IdType="pubmed">35721085</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Xu M, Min X, Wu K, Zhang T, Li K, et al. TWEAK/Fn14 activation participates in Ro52-mediated photosensitization in cutaneous lupus erythematosus. Front Immunol. 2017;8:651. doi: 10.3389/fimmu.2017.00651.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00651</ArticleId><ArticleId IdType="pmc">PMC5449764</ArticleId><ArticleId IdType="pubmed">28620393</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich A, Meurer M, Viehweg A, Muller DJ. Narrow-band UVB-induced externalization of selected nuclear antigens in keratinocytes: implications for lupus erythematosus pathogenesis. Photochem Photobiol. 2009;85:1&#x2013;7. doi: 10.1111/j.1751-1097.2008.00480.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-1097.2008.00480.x</ArticleId><ArticleId IdType="pubmed">19076311</ArticleId></ArticleIdList></Reference><Reference><Citation>Greiling TM, Dehner C, Chen X, Hughes K, I&#xf1;iguez AJ, Boccitto M, et al. Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus. Sci Transl Med. 2018 doi: 10.1126/scitranslmed.aan2306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aan2306</ArticleId><ArticleId IdType="pmc">PMC5918293</ArticleId><ArticleId IdType="pubmed">29593104</ArticleId></ArticleIdList></Reference><Reference><Citation>Meller S, Winterberg F, Gilliet M, M&#xfc;ller A, Lauceviciute I, Rieker J, et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 2005;52:1504&#x2013;1516. doi: 10.1002/art.21034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21034</ArticleId><ArticleId IdType="pubmed">15880822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, Zahn S, Mikus S, Wiechert A, Bieber T, T&#xfc;ting T. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol. 2007;157:752&#x2013;757. doi: 10.1111/j.1365-2133.2007.08137.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2007.08137.x</ArticleId><ArticleId IdType="pubmed">17714558</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa F, Itoh T, Wakita H, Yagi H, Tokura Y, Norris DA, Takigawa M. Keratinocytes from patients with lupus erythematosus show enhanced cytotoxicity to ultraviolet radiation and to antibody-mediated cytotoxicity. Clin Exp Immunol. 1999;118:164&#x2013;170. doi: 10.1046/j.1365-2249.1999.01026.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1999.01026.x</ArticleId><ArticleId IdType="pmc">PMC1905409</ArticleId><ArticleId IdType="pubmed">10540174</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Herrmann M, Kleber S, Beckmann-Welle M, Fehsel K, Martin-Villalba A, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum. 2006;54:939&#x2013;950. doi: 10.1002/art.21658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21658</ArticleId><ArticleId IdType="pubmed">16511837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi A, Nagafuchi H, Ito I, Hirota K, Yoshida M, Ozaki S. Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod Rheumatol. 2009;19:283&#x2013;292. doi: 10.1007/s10165-009-0151-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10165-009-0151-7</ArticleId><ArticleId IdType="pubmed">19214652</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholtissek B, Zahn S, Maier J, Klaeschen S, Braegelmann C, Hoelzel M, et al. Immunostimulatory endogenous nucleic acids drive the lesional inflammation in cutaneous lupus erythematosus. J Invest Dermatol. 2017;137:1484&#x2013;1492. doi: 10.1016/j.jid.2017.03.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2017.03.018</ArticleId><ArticleId IdType="pubmed">28351661</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar MK, Hile GA, Tsoi LC, Xing X, Liu J, Liang Y, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77:1653&#x2013;1664. doi: 10.1136/annrheumdis-2018-213197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213197</ArticleId><ArticleId IdType="pmc">PMC6185784</ArticleId><ArticleId IdType="pubmed">30021804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahn S, Rehk&#xe4;mper C, K&#xfc;mmerer BM, Ferring-Schmidt S, Bieber T, T&#xfc;ting T, Wenzel J. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFN&#x3bb;) in cutaneous lupus erythematosus. J Invest Dermatol. 2011;131:133&#x2013;140. doi: 10.1038/jid.2010.244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2010.244</ArticleId><ArticleId IdType="pubmed">20720564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, T&#xfc;ting T. Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol. 2007;16:454&#x2013;463. doi: 10.1111/j.1600-0625.2007.00556.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0625.2007.00556.x</ArticleId><ArticleId IdType="pubmed">17437489</ArticleId></ArticleIdList></Reference><Reference><Citation>Braegelmann C, Fetter T, Niebel D, Dietz L, Bieber T, Wenzel J. Immunostimulatory endogenous nucleic acids perpetuate interface dermatitis-translation of pathogenic fundamentals into an in vitro model. Front Immunol. 2020;11:622511. doi: 10.3389/fimmu.2020.622511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.622511</ArticleId><ArticleId IdType="pmc">PMC7831152</ArticleId><ArticleId IdType="pubmed">33505404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopfnagel V, Wittmann M, Werfel T. Human keratinocytes express AIM2 and respond to dsDNA with IL-1&#x3b2; secretion. Exp Dermatol. 2011;20:1027&#x2013;1029. doi: 10.1111/j.1600-0625.2011.01382.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0625.2011.01382.x</ArticleId><ArticleId IdType="pubmed">22092578</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiducci C, Tripodo C, Gong M, Sangaletti S, Colombo MP, Coffman RL, Barrat FJ. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med. 2010;207:2931&#x2013;2942. doi: 10.1084/jem.20101048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20101048</ArticleId><ArticleId IdType="pmc">PMC3005224</ArticleId><ArticleId IdType="pubmed">21115693</ArticleId></ArticleIdList></Reference><Reference><Citation>Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005;115:407&#x2013;417. doi: 10.1172/JCI23025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI23025</ArticleId><ArticleId IdType="pmc">PMC544604</ArticleId><ArticleId IdType="pubmed">15668740</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330:827&#x2013;830. doi: 10.1126/science.1195300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1195300</ArticleId><ArticleId IdType="pubmed">21051638</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159:237&#x2013;243. doi: 10.1016/s0002-9440(10)61689-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9440(10)61689-6</ArticleId><ArticleId IdType="pmc">PMC1850412</ArticleId><ArticleId IdType="pubmed">11438470</ArticleId></ArticleIdList></Reference><Reference><Citation>Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, Vicari A, Trinchieri G. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med. 2005;201:1157&#x2013;1167. doi: 10.1084/jem.20041930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041930</ArticleId><ArticleId IdType="pmc">PMC2213121</ArticleId><ArticleId IdType="pubmed">15795237</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermi W, Lonardi S, Morassi M, Rossini C, Tardanico R, Venturini M, et al. Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology. 2009;214:877&#x2013;886. doi: 10.1016/j.imbio.2009.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2009.06.013</ArticleId><ArticleId IdType="pubmed">19625100</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vos L, Guel T, Niebel D, Bald S, ter Steege A, Bieber T, Wenzel J. Characterization of B cells in lupus erythematosus skin biopsies in the context of different immune cell infiltration patterns. Front Med (Lausanne). 2022;9:1037408. doi: 10.3389/fmed.2022.1037408.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1037408</ArticleId><ArticleId IdType="pmc">PMC9685332</ArticleId><ArticleId IdType="pubmed">36438026</ArticleId></ArticleIdList></Reference><Reference><Citation>Billi AC, Ma F, Plazyo O, Gharaee-Kermani M, Wasikowski R, Hile GA, et al. Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci Transl Med. 2022;14:eabn2263. doi: 10.1126/scitranslmed.abn2263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn2263</ArticleId><ArticleId IdType="pmc">PMC9169615</ArticleId><ArticleId IdType="pubmed">35476593</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Investig. 2019;129:1359&#x2013;1371. doi: 10.1172/JCI124466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124466</ArticleId><ArticleId IdType="pmc">PMC6391094</ArticleId><ArticleId IdType="pubmed">30645203</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med. 2001;194:1823&#x2013;1834. doi: 10.1084/jem.194.12.1823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.194.12.1823</ArticleId><ArticleId IdType="pmc">PMC2193584</ArticleId><ArticleId IdType="pubmed">11748283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsker D, Saurat J-H. Neutrophilic cutaneous lupus erythematosus. At the edge between innate and acquired immunity? Dermatology. 2008;216:283&#x2013;286. doi: 10.1159/000113940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000113940</ArticleId><ArticleId IdType="pubmed">18230975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res. 2014 doi: 10.1155/2014/419029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/419029</ArticleId><ArticleId IdType="pmc">PMC4017881</ArticleId><ArticleId IdType="pubmed">24864268</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh D, Tsokos GC, Kyttaris VC. c-Jun and Ets2 proteins regulate expression of spleen tyrosine kinase in T cells. J Biol Chem. 2012;287:11833&#x2013;11841. doi: 10.1074/jbc.M111.333997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.333997</ArticleId><ArticleId IdType="pmc">PMC3320931</ArticleId><ArticleId IdType="pubmed">22354960</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyttaris VC, Wang Y, Juang Y-T, Weinstein A, Tsokos GC. Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J Immunol. 2007;178:1960&#x2013;1966. doi: 10.4049/jimmunol.178.3.1960.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.3.1960</ArticleId><ArticleId IdType="pubmed">17237447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kow NY, Mak A. Costimulatory pathways: physiology and potential therapeutic manipulation in systemic lupus erythematosus. Clin Dev Immunol. 2013 doi: 10.1155/2013/245928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/245928</ArticleId><ArticleId IdType="pmc">PMC3755444</ArticleId><ArticleId IdType="pubmed">24000287</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol. 2001;166:4216&#x2013;4222. doi: 10.4049/jimmunol.166.6.4216.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.166.6.4216</ArticleId><ArticleId IdType="pubmed">11238674</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisp&#xed;n JC, Oukka M, Bayliss G, Cohen RA, van Beek CA, Stillman IE, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008;181:8761&#x2013;8766. doi: 10.4049/jimmunol.181.12.8761.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.12.8761</ArticleId><ArticleId IdType="pmc">PMC2596652</ArticleId><ArticleId IdType="pubmed">19050297</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, W&#xf6;renk&#xe4;mper E, Freutel S, Henze S, Haller O, Bieber T, T&#xfc;ting T. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005;205:435&#x2013;442. doi: 10.1002/path.1721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1721</ArticleId><ArticleId IdType="pubmed">15685590</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassi M, Capello F, Bertolino L, Seia Z, Pippione M. Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis. Clin Exp Dermatol. 2009;34:910&#x2013;914. doi: 10.1111/j.1365-2230.2009.03297.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2230.2009.03297.x</ArticleId><ArticleId IdType="pubmed">19456762</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, Uerlich M, W&#xf6;rrenk&#xe4;mper E, Freutel S, Bieber T, T&#xfc;ting T. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol. 2005;153:1011&#x2013;1015. doi: 10.1111/j.1365-2133.2005.06784.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2005.06784.x</ArticleId><ArticleId IdType="pubmed">16225615</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddadi N-S, Mande P, Brodeur TY, Hao K, Ryan GE, Moses S, et al. Th2 to Th1 transition is required for induction of skin lesions in an inducible and recurrent murine model of cutaneous lupus-like inflammation. Front Immunol. 2022;13:883375. doi: 10.3389/fimmu.2022.883375.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.883375</ArticleId><ArticleId IdType="pmc">PMC9271959</ArticleId><ArticleId IdType="pubmed">35833127</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Murphy TL, Ouyang W, Murphy KM. Induction of interferon-&#x3b3; production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur J Immunol. 1999;29:548&#x2013;555. doi: 10.1002/(SICI)1521-4141(199902)29:02&lt;548::AID-IMMU548&gt;3.0.CO;2-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1521-4141(199902)29:02&lt;548::AID-IMMU548&gt;3.0.CO;2-Z</ArticleId><ArticleId IdType="pubmed">10064070</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima M, Nakajima A, Kayagaki N, Honda M, Yagita H, Okumura K. Expression of Fas ligand and its receptor in cutaneous lupus: implication in tissue injury. Clin Immunol Immunopathol. 1997;83:223&#x2013;229. doi: 10.1006/clin.1997.4352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clin.1997.4352</ArticleId><ArticleId IdType="pubmed">9175910</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvi V, Vermi W, Cavani A, Lonardi S, Carbone T, Facchetti F, et al. IL-21 May promote granzyme B-dependent NK/plasmacytoid dendritic cell functional interaction in cutaneous lupus erythematosus. J Invest Dermatol. 2017;137:1493&#x2013;1500. doi: 10.1016/j.jid.2017.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2017.03.016</ArticleId><ArticleId IdType="pubmed">28344062</ArticleId></ArticleIdList></Reference><Reference><Citation>Karrich JJ, Jachimowski LCM, Nagasawa M, Kamp A, Balzarolo M, Wolkers MC, et al. IL-21-stimulated human plasmacytoid dendritic cells secrete granzyme B, which impairs their capacity to induce T-cell proliferation. Blood. 2013;121:3103&#x2013;3111. doi: 10.1182/blood-2012-08-452995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-08-452995</ArticleId><ArticleId IdType="pmc">PMC3630825</ArticleId><ArticleId IdType="pubmed">23407551</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivakumar S, Tsokos GC, Datta SK. T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol. 1989;143:103&#x2013;112. doi: 10.4049/jimmunol.143.1.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.143.1.103</ArticleId><ArticleId IdType="pubmed">2525144</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan S, Zordan T, Tsokos GC, Datta SK. Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4-8- T helper cell lines that express the gamma delta T-cell antigen receptor. Proc Natl Acad Sci U S A. 1990;87:7020&#x2013;7024. doi: 10.1073/pnas.87.18.7020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.18.7020</ArticleId><ArticleId IdType="pmc">PMC54674</ArticleId><ArticleId IdType="pubmed">2144899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Kaliyaperumal A, Boumpas DT, Datta SK. Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest. 1999;104:345&#x2013;355. doi: 10.1172/JCI6801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI6801</ArticleId><ArticleId IdType="pmc">PMC408421</ArticleId><ArticleId IdType="pubmed">10430616</ArticleId></ArticleIdList></Reference><Reference><Citation>Voll RE, Roth EA, Girkontaite I, Fehr H, Herrmann M, Lorenz HM, Kalden JR. Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum. 1997;40:2162&#x2013;2171. doi: 10.1002/art.1780401210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780401210</ArticleId><ArticleId IdType="pubmed">9416853</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Zhang X, Zhao M, Lu Q. DNA demethylation of the perforin promoter in CD4(+) T cells from patients with subacute cutaneous lupus erythematosus. J Dermatol Sci. 2009;56:33&#x2013;36. doi: 10.1016/j.jdermsci.2009.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdermsci.2009.06.010</ArticleId><ArticleId IdType="pubmed">19651491</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz B, Fritzsching B, Riehl A, Oberle N, Klemke C-D, Sykora J, et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum. 2007;56:1910&#x2013;1920. doi: 10.1002/art.22699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22699</ArticleId><ArticleId IdType="pubmed">17530636</ArticleId></ArticleIdList></Reference><Reference><Citation>Filaci G, Bacilieri S, Fravega M, Monetti M, Contini P, Ghio M, et al. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol. 2001;166:6452&#x2013;6457. doi: 10.4049/jimmunol.166.10.6452.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.166.10.6452</ArticleId><ArticleId IdType="pubmed">11342672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambichler T, P&#xe4;tzholz J, Schmitz L, Lahner N, Kreuter A. FOXP3+ and CD39+ regulatory T cells in subtypes of cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol. 2015;29:1972&#x2013;1977. doi: 10.1111/jdv.13123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.13123</ArticleId><ArticleId IdType="pubmed">25808110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kil LP, Hendriks RW. Aberrant B cell selection and activation in systemic lupus erythematosus. Int Rev Immunol. 2013;32:445&#x2013;470. doi: 10.3109/08830185.2013.786712.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08830185.2013.786712</ArticleId><ArticleId IdType="pubmed">23768157</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001;2:764&#x2013;766. doi: 10.1038/ni0901-764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni0901-764</ArticleId><ArticleId IdType="pubmed">11526379</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerman I, Mitchell DC, Richardson CT. Human cutaneous B cells: what do we really know? Ann Transl Med. 2021;9:440. doi: 10.21037/atm-20-5185.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-5185</ArticleId><ArticleId IdType="pmc">PMC8033329</ArticleId><ArticleId IdType="pubmed">33842661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiefer K, Oropallo MA, Cancro MP, Marshak-Rothstein A. Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol. 2012;90:498&#x2013;504. doi: 10.1038/icb.2012.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2012.10</ArticleId><ArticleId IdType="pmc">PMC3701256</ArticleId><ArticleId IdType="pubmed">22430248</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S, Li Q, Zhou S, Zhao M, Lu L, Wu H, Lu Q. A novel humanized cutaneous lupus erythematosus mouse model mediated by IL-21-induced age-associated B cells. J Autoimmun. 2021;123:102686. doi: 10.1016/j.jaut.2021.102686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102686</ArticleId><ArticleId IdType="pubmed">34325305</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisp&#xed;n JC, Tsokos GC. IL-17 in systemic lupus erythematosus. J Biomed Biotechnol. 2010 doi: 10.1155/2010/943254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2010/943254</ArticleId><ArticleId IdType="pmc">PMC2850519</ArticleId><ArticleId IdType="pubmed">20379379</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontheimer RD, Maddison PJ, Reichlin M, Jordon RE, Stastny P, Gilliam JN. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med. 1982;97:664&#x2013;671. doi: 10.7326/0003-4819-97-5-664.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-97-5-664</ArticleId><ArticleId IdType="pubmed">6982644</ArticleId></ArticleIdList></Reference><Reference><Citation>Patsinakidis N, Gambichler T, Lahner N, Moellenhoff K, Kreuter A. Cutaneous characteristics and association with antinuclear antibodies in 402 patients with different subtypes of lupus erythematosus. J Eur Acad Dermatol Venereol. 2016;30:2097&#x2013;2104. doi: 10.1111/jdv.13769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.13769</ArticleId><ArticleId IdType="pubmed">27431977</ArticleId></ArticleIdList></Reference><Reference><Citation>Garelli CJ, Refat MA, Nanaware PP, Ramirez-Ortiz ZG, Rashighi M, Richmond JM. Current insights in cutaneous lupus erythematosus immunopathogenesis. Front Immunol. 2020;11:1353. doi: 10.3389/fimmu.2020.01353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01353</ArticleId><ArticleId IdType="pmc">PMC7343764</ArticleId><ArticleId IdType="pubmed">32714331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasicek CA, Reichlin M. Clinical and serological differences between systemic lupus erythematosus patients with antibodies to Ro versus patients with antibodies to Ro and La. J Clin Invest. 1982;69:835&#x2013;843. doi: 10.1172/jci110523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci110523</ArticleId><ArticleId IdType="pmc">PMC370138</ArticleId><ArticleId IdType="pubmed">6804494</ArticleId></ArticleIdList></Reference><Reference><Citation>Abernathy-Close L, Lazar S, Stannard J, Tsoi LC, Eddy S, Rizvi SM, et al. B cell signatures distinguish cutaneous lupus erythematosus subtypes and the presence of systemic disease activity. Front Immunol. 2021;12:775353. doi: 10.3389/fimmu.2021.775353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.775353</ArticleId><ArticleId IdType="pmc">PMC8640489</ArticleId><ArticleId IdType="pubmed">34868043</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks SA, Wei C, Bugrovsky R, Hill A, Wang X, Rossi FM, et al. B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus. Ann Rheum Dis. 2021;80:1190&#x2013;1200. doi: 10.1136/annrheumdis-2021-220349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220349</ArticleId><ArticleId IdType="pmc">PMC8906255</ArticleId><ArticleId IdType="pubmed">34083207</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogame T, Yamashita R, Hirata M, Kataoka TR, Kamido H, Ueshima C, et al. Analysis of possible structures of inducible skin-associated lymphoid tissue in lupus erythematosus profundus. J Dermatol. 2018;45:1117&#x2013;1121. doi: 10.1111/1346-8138.14498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1346-8138.14498</ArticleId><ArticleId IdType="pubmed">29897143</ArticleId></ArticleIdList></Reference><Reference><Citation>Fetter T, Niebel D, Braegelmann C, Wenzel J. Skin-associated B cells in the pathogenesis of cutaneous autoimmune diseases-implications for therapeutic approaches. Cells. 2020 doi: 10.3390/cells9122627.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9122627</ArticleId><ArticleId IdType="pmc">PMC7762338</ArticleId><ArticleId IdType="pubmed">33297481</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinmetz OM, Velden J, Kneissler U, Marx M, Klein A, Helmchen U, et al. Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis. Kidney Int. 2008;74:448&#x2013;457. doi: 10.1038/ki.2008.191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2008.191</ArticleId><ArticleId IdType="pubmed">18528326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol. 2011;186:1849&#x2013;1860. doi: 10.4049/jimmunol.1001983.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001983</ArticleId><ArticleId IdType="pmc">PMC3124090</ArticleId><ArticleId IdType="pubmed">21187439</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Yang J, Chu Y, Xue Y, Xuan D, Zheng S, Zou H. T follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus. PLoS ONE. 2014;9:e88441. doi: 10.1371/journal.pone.0088441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0088441</ArticleId><ArticleId IdType="pmc">PMC3925141</ArticleId><ArticleId IdType="pubmed">24551101</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Yang M, Di Long LQ, Zhao M, Wu H, Lu Q. Abnormal expression of BAFF and its receptors in peripheral blood and skin lesions from systemic lupus erythematosus patients. Autoimmunity. 2020;53:192&#x2013;200. doi: 10.1080/08916934.2020.1736049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916934.2020.1736049</ArticleId><ArticleId IdType="pubmed">32157911</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, Landmann A, Vorwerk G, Kuhn A. High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus. Exp Dermatol. 2018;27:95&#x2013;97. doi: 10.1111/exd.13419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/exd.13419</ArticleId><ArticleId IdType="pubmed">28833566</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong BF, Tseng L-C, Kim A, Miller RT, Yancey KB, Hosler GA. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. J Dermatol Sci. 2014;73:216&#x2013;224. doi: 10.1016/j.jdermsci.2013.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdermsci.2013.11.007</ArticleId><ArticleId IdType="pmc">PMC3946198</ArticleId><ArticleId IdType="pubmed">24315762</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2:465&#x2013;475. doi: 10.1038/nri844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri844</ArticleId><ArticleId IdType="pubmed">12094221</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Guo Q, Wu C, Sterlin D, Goswami S, Zhang Y, et al. Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients. Cell Mol Immunol. 2019;16:367&#x2013;379. doi: 10.1038/s41423-018-0010-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-018-0010-6</ArticleId><ArticleId IdType="pmc">PMC6461980</ArticleId><ArticleId IdType="pubmed">29563616</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkiel S, Barlev AN, Atisha-Fregoso Y, Suurmond J, Diamond B. Plasma cell differentiation pathways in systemic lupus erythematosus. Front Immunol. 2018;9:427. doi: 10.3389/fimmu.2018.00427.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00427</ArticleId><ArticleId IdType="pmc">PMC5845388</ArticleId><ArticleId IdType="pubmed">29556239</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaaslan S, Tomayko MM. A niche for plasma cells: the skin. J Invest Dermatol. 2019;139:2411&#x2013;2414. doi: 10.1016/j.jid.2019.06.133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2019.06.133</ArticleId><ArticleId IdType="pubmed">31753124</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller EJ, Patel NB, Patt M, Nguyen JK, J&#xf8;rgensen TN. Partial protection from lupus-like disease by B-cell specific type I interferon receptor deficiency. Front Immunol. 2020;11:616064. doi: 10.3389/fimmu.2020.616064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.616064</ArticleId><ArticleId IdType="pmc">PMC7821742</ArticleId><ArticleId IdType="pubmed">33488628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Wang J, Kumar V, Karnell JL, Naiman B, Gross PS, et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE. Nat Commun. 2018;9:1758. doi: 10.1038/s41467-018-03750-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03750-7</ArticleId><ArticleId IdType="pmc">PMC5931508</ArticleId><ArticleId IdType="pubmed">29717110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma K, Li J, Wang X, Lin X, Du W, Yang X, et al. TLR4+CXCR4+ plasma cells drive nephritis development in systemic lupus erythematosus. Ann Rheum Dis. 2018;77:1498&#x2013;1506. doi: 10.1136/annrheumdis-2018-213615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213615</ArticleId><ArticleId IdType="pubmed">29925508</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Teixeira L, In&#xea;s L, Carvalheiro T, Gon&#xe7;alves A, Martinho A, et al. NK cells dysfunction in systemic lupus erythematosus: relation to disease activity. Clin Rheumatol. 2013;32:805&#x2013;813. doi: 10.1007/s10067-013-2176-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-013-2176-8</ArticleId><ArticleId IdType="pubmed">23377197</ArticleId></ArticleIdList></Reference><Reference><Citation>Schepis D, Gunnarsson I, Eloranta M-L, Lampa J, Jacobson SH, K&#xe4;rre K, Berg L. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology. 2009;126:140&#x2013;146. doi: 10.1111/j.1365-2567.2008.02887.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2008.02887.x</ArticleId><ArticleId IdType="pmc">PMC2632704</ArticleId><ArticleId IdType="pubmed">18564343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann SC, Bosma A, Bruckner-Tuderman L, Vukmanovic-Stejic M, Jury EC, Isenberg DA, Mauri C. Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus. J Dermatol Sci. 2013;71:22&#x2013;28. doi: 10.1016/j.jdermsci.2013.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdermsci.2013.04.012</ArticleId><ArticleId IdType="pubmed">23664188</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Angarita A, Arag&#xf3;n CC, Tob&#xf3;n GJ. Cathelicidin LL-37: a new important molecule in the pathophysiology of systemic lupus erythematosus. J Transl Autoimmun. 2020;3:100029. doi: 10.1016/j.jtauto.2019.100029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2019.100029</ArticleId><ArticleId IdType="pmc">PMC7388365</ArticleId><ArticleId IdType="pubmed">32743514</ArticleId></ArticleIdList></Reference><Reference><Citation>Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18:134&#x2013;147. doi: 10.1038/nri.2017.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.105</ArticleId><ArticleId IdType="pubmed">28990587</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Su K. Neutrophil extracellular traps and systemic lupus erythematosus. J Clin Cell Immunol. 2013 doi: 10.4172/2155-9899.1000139.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2155-9899.1000139</ArticleId><ArticleId IdType="pmc">PMC3826916</ArticleId><ArticleId IdType="pubmed">24244889</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistry P, Nakabo S, O'Neil L, Goel RR, Jiang K, Carmona-Rivera C, et al. Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci. 2019;116:25222&#x2013;25228. doi: 10.1073/pnas.1908576116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1908576116</ArticleId><ArticleId IdType="pmc">PMC6911190</ArticleId><ArticleId IdType="pubmed">31754025</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlucci PM, Purmalek MM, Dey AK, Temesgen-Oyelakin Y, Sakhardande S, Joshi AA, et al. Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. JCI Insight. 2018 doi: 10.1172/jci.insight.99276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.99276</ArticleId><ArticleId IdType="pmc">PMC5931124</ArticleId><ArticleId IdType="pubmed">29669944</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakkim A, F&#xfc;rnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci. 2010;107:9813&#x2013;9818. doi: 10.1073/pnas.0909927107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0909927107</ArticleId><ArticleId IdType="pmc">PMC2906830</ArticleId><ArticleId IdType="pubmed">20439745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3:73ra19. doi: 10.1126/scitranslmed.3001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001180</ArticleId><ArticleId IdType="pmc">PMC3399524</ArticleId><ArticleId IdType="pubmed">21389263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuter A, Jaouhar M, Skrygan M, Tigges C, St&#xfc;cker M, Altmeyer P, et al. Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;65:125&#x2013;133. doi: 10.1016/j.jaad.2010.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2010.12.012</ArticleId><ArticleId IdType="pubmed">21353331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C-L, Zhang F-Z, Li P, Bi L-Q. LL-37 expression in the skin in systemic lupus erythematosus. Lupus. 2011;20:904&#x2013;911. doi: 10.1177/0961203311398515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311398515</ArticleId><ArticleId IdType="pubmed">21562016</ArticleId></ArticleIdList></Reference><Reference><Citation>Safi R, Al-Hage J, Abbas O, Kibbi A-G, Nassar D. Investigating the presence of neutrophil extracellular traps in cutaneous lesions of different subtypes of lupus erythematosus. Exp Dermatol. 2019;28:1348&#x2013;1352. doi: 10.1111/exd.14040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/exd.14040</ArticleId><ArticleId IdType="pubmed">31529548</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lee PY, Reeves WH. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz) 2010;58:355&#x2013;364. doi: 10.1007/s00005-010-0093-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-010-0093-y</ArticleId><ArticleId IdType="pmc">PMC3785254</ArticleId><ArticleId IdType="pubmed">20676786</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294:1540&#x2013;1543. doi: 10.1126/science.1064890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1064890</ArticleId><ArticleId IdType="pubmed">11711679</ArticleId></ArticleIdList></Reference><Reference><Citation>Tas SW, Quartier P, Botto M, Fossati-Jimack L. Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann Rheum Dis. 2006;65:216&#x2013;221. doi: 10.1136/ard.2005.037143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.037143</ArticleId><ArticleId IdType="pmc">PMC1798004</ArticleId><ArticleId IdType="pubmed">16014673</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CGM. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis. 2006;65:57&#x2013;63. doi: 10.1136/ard.2005.035733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.035733</ArticleId><ArticleId IdType="pmc">PMC1797975</ArticleId><ArticleId IdType="pubmed">15919679</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677&#x2013;686. doi: 10.1016/j.it.2004.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2004.09.015</ArticleId><ArticleId IdType="pubmed">15530839</ArticleId></ArticleIdList></Reference><Reference><Citation>Labonte AC, Kegerreis B, Geraci NS, Bachali P, Madamanchi S, Robl R, et al. Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus. PLoS ONE. 2018;13:e0208132. doi: 10.1371/journal.pone.0208132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0208132</ArticleId><ArticleId IdType="pmc">PMC6298676</ArticleId><ArticleId IdType="pubmed">30562343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi S, Saghaeian-Jazi M, Sedighi S, Memarian A. Immunomodulation in systemic lupus erythematosus: induction of M2 population in monocyte-derived macrophages by pioglitazone. Lupus. 2017;26:1318&#x2013;1327. doi: 10.1177/0961203317701842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317701842</ArticleId><ArticleId IdType="pubmed">28457196</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Yang Y, Zhu X, Huang L, Xu J. Macrophage polarization modulates development of systemic lupus erythematosus. Cell Physiol Biochem. 2015;37:1279&#x2013;1288. doi: 10.1159/000430251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000430251</ArticleId><ArticleId IdType="pubmed">26431544</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Xia Y, Yang Q, Zhao Y. The contribution of macrophages to systemic lupus erythematosus. Clin Immunol. 2019;207:1&#x2013;9. doi: 10.1016/j.clim.2019.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2019.06.009</ArticleId><ArticleId IdType="pubmed">31255802</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Huang X, Xu S, Li L, Wu W, Dai Y, et al. Decreased miR-4512 Levels in monocytes and macrophages of individuals with systemic lupus erythematosus contribute to innate immune activation and Neutrsophil NETosis by targeting TLR4 and CXCL2. Front Immunol. 2021;12:756825. doi: 10.3389/fimmu.2021.756825.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.756825</ArticleId><ArticleId IdType="pmc">PMC8552026</ArticleId><ArticleId IdType="pubmed">34721432</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayard D, Franc&#xe8;s C, Amoura Z, Breillat P, Mathian A, Senet P, et al. Prevalence and factors associated with long-term remission in cutaneous lupus: a longitudinal cohort study of 141 cases. J Am Acad Dermatol. 2022;87:323&#x2013;332. doi: 10.1016/j.jaad.2022.03.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2022.03.056</ArticleId><ArticleId IdType="pubmed">35390427</ArticleId></ArticleIdList></Reference><Reference><Citation>Worm M, Zidane M, Eisert L, Fischer-Betz R, Foeldvari I, G&#xfc;nther C, et al. S2k guideline: Diagnosis and management of cutaneous lupus erythematosus - Part 2: Therapy, risk factors and other special topics. J Dtsch Dermatol Ges. 2021;19:1371&#x2013;1395. doi: 10.1111/ddg.14491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ddg.14491</ArticleId><ArticleId IdType="pubmed">34338428</ArticleId></ArticleIdList></Reference><Reference><Citation>Barua DP, Chowdhury MIH, Mowla MR, Reich A, Murrell D, Ruzicka T. Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus. Dermatol Ther. 2021;34:e14675. doi: 10.1111/dth.14675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.14675</ArticleId><ArticleId IdType="pubmed">33320408</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel J, Vazquez T, Chin F, Keyes E, Yan D, Diaz D, et al. Multidimensional immune profiling of cutaneous lupus erythematosus in vivo stratified by patient responses to antimalarials. Arthritis Rheumatol. 2022 doi: 10.1002/art.42235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42235</ArticleId><ArticleId IdType="pubmed">35583812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Aberer E, Bata-Cs&#xf6;rg&#x151; Z, Caproni M, Dreher A, Frances C, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) J Eur Acad Dermatol Venereol. 2017;31:389&#x2013;404. doi: 10.1111/jdv.14053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.14053</ArticleId><ArticleId IdType="pubmed">27859683</ArticleId></ArticleIdList></Reference><Reference><Citation>Worm M, Zidane M, Eisert L, Fischer-Betz R, Foeldvari I, G&#xfc;nther C, et al. S2k guideline: Diagnosis and management of cutaneous lupus erythematosus&#x2014;part 1: classification, diagnosis, prevention, activity scores. J Dtsch Dermatol Ges. 2021;19:1236&#x2013;1247. doi: 10.1111/ddg.14492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ddg.14492</ArticleId><ArticleId IdType="pubmed">34390136</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Kane D, McCourt C, Meggitt S, D'Cruz DP, Orteu CH, Benton E, et al. British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021. Br J Dermatol. 2021;185:1112&#x2013;1123. doi: 10.1111/bjd.20597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.20597</ArticleId><ArticleId IdType="pubmed">34170012</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007;156:1321&#x2013;1327. doi: 10.1111/j.1365-2133.2007.07826.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2007.07826.x</ArticleId><ArticleId IdType="pubmed">17408395</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736&#x2013;745. doi: 10.1136/annrheumdis-2019-215089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyes E, Jobanputra A, Feng R, Grinnell M, Vazquez T, Diaz D, Werth VP. Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: A cohort study. J Am Acad Dermatol. 2022;87:447&#x2013;448. doi: 10.1016/j.jaad.2021.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2021.09.017</ArticleId><ArticleId IdType="pmc">PMC10233728</ArticleId><ArticleId IdType="pubmed">34537250</ArticleId></ArticleIdList></Reference><Reference><Citation>Laosakul K, Chiewchanvit S, Chuamanochan M, Tovanabutra N. Acitretin treatment in antimalarial-refractory/intolerant discoid lupus erythematosus: a prospective, open-label, uncontrolled study. Lupus. 2022;31:575&#x2013;581. doi: 10.1177/09612033221086878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221086878</ArticleId><ArticleId IdType="pubmed">35306922</ArticleId></ArticleIdList></Reference><Reference><Citation>Aitmehdi R, Arnaud L, Franc&#xe8;s C, Senet P, Monfort J-B, de Risi-Pugliese T, et al. Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: a multicenter retrospective observational study of 40 patients. J Am Acad Dermatol. 2021;84:1171&#x2013;1174. doi: 10.1016/j.jaad.2020.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.11.014</ArticleId><ArticleId IdType="pubmed">33221461</ArticleId></ArticleIdList></Reference><Reference><Citation>Reymann V, Bessis D, Bergeret B, Lipsker D, Du-Thanh A, Terrail N, et al. Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases. J Eur Acad Dermatol Venereol. 2021;35:e113&#x2013;e115. doi: 10.1111/jdv.16839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.16839</ArticleId><ArticleId IdType="pubmed">32730681</ArticleId></ArticleIdList></Reference><Reference><Citation>Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27:391&#x2013;404. doi: 10.1016/j.berh.2013.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2013.07.008</ArticleId><ArticleId IdType="pmc">PMC3927537</ArticleId><ArticleId IdType="pubmed">24238695</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020;32:208&#x2013;214. doi: 10.1097/BOR.0000000000000704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000704</ArticleId><ArticleId IdType="pmc">PMC7357847</ArticleId><ArticleId IdType="pubmed">32141953</ArticleId></ArticleIdList></Reference><Reference><Citation>Braegelmann C, Niebel D, Wenzel J. Targeted therapies in autoimmune skin diseases. J Invest Dermatol. 2022;142:969&#x2013;975.e7. doi: 10.1016/j.jid.2021.08.439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2021.08.439</ArticleId><ArticleId IdType="pubmed">34756580</ArticleId></ArticleIdList></Reference><Reference><Citation>Petty AJ, Floyd L, Henderson C, Nicholas MW. Cutaneous lupus erythematosus: progress and challenges. Curr Allergy Asthma Rep. 2020;20:12. doi: 10.1007/s11882-020-00906-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11882-020-00906-8</ArticleId><ArticleId IdType="pmc">PMC7548961</ArticleId><ArticleId IdType="pubmed">32248318</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Kondo K, Ichibori A, Yanai Y, Susuta Y, Inoue S, Takeuchi T. Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: a multicenter, open-label exploratory study. Lupus. 2020;29:1902&#x2013;1913. doi: 10.1177/0961203320966385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320966385</ArticleId><ArticleId IdType="pubmed">33115374</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Bruce IN, D&#xf6;rner T, Leon MG, Leszczy&#x144;ski P, Urowitz M, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:5397&#x2013;5407. doi: 10.1093/rheumatology/keab381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab381</ArticleId><ArticleId IdType="pmc">PMC9194804</ArticleId><ArticleId IdType="pubmed">33956056</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchao N, Sarkar N, Hu X, Zhang R, Milmont C, Shi Jin Y, et al. AB0432 efavaleukin alfa, a novel IL-2 mutein, selectively expands regulatory T cells in patients with SLE: final results of a phase 1b multiple ascending dose study. Ann Rheum Dis. 2022;81:1343&#x2013;1344. doi: 10.1136/annrheumdis-2022-eular.2244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.2244</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov&#xe1; D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918&#x2013;3930. doi: 10.1002/art.30613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30613</ArticleId><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht P, Borghoff K, O'Dell JR, Hearth-Holmes M. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus. 2017;26:857&#x2013;864. doi: 10.1177/0961203316682097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316682097</ArticleId><ArticleId IdType="pubmed">28121495</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch-Amate X, Morgado-Carrasco D, Combalia A, Giavedoni P, Espinosa G, Mascar&#xf3; JM. Successful treatment of two cases of refractory cutaneous lupus erythematosus with belimumab. Indian J Dermatol Venereol Leprol. 2021;87:421&#x2013;424. doi: 10.25259/IJDVL_1032_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.25259/IJDVL_1032_18</ArticleId><ArticleId IdType="pubmed">33943067</ArticleId></ArticleIdList></Reference><Reference><Citation>Dresco F, Puzenat E, Delobeau M, Salard D, Lihoreau T, Pelletier F, Aubin F. Lupus &#xe9;ryth&#xe9;mateux cutan&#xe9;s r&#xe9;fractaires trait&#xe9;s par b&#xe9;limumab : &#xe9;tude descriptive monocentrique [Resistant and progressive cutaneous lupus erythematosus treated with belimumab: A retrospective monocentric study] Rev Med Intern. 2020;41:152&#x2013;159. doi: 10.1016/j.revmed.2019.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.revmed.2019.12.004</ArticleId><ArticleId IdType="pubmed">31980188</ArticleId></ArticleIdList></Reference><Reference><Citation>Salle R, Chasset F, Kottler D, Picard-Dahan C, Jannic A, Mekki N, et al. Belimumab for refractory manifestations of cutaneous lupus: A multicenter, retrospective observational study of 16 patients. J Am Acad Dermatol. 2020;83:1816&#x2013;1819. doi: 10.1016/j.jaad.2020.05.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.05.058</ArticleId><ArticleId IdType="pubmed">32439463</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrente-Segarra V, Peramiquel L, Bonet M. Belimumab in subacute cutaneous lupus erythematosus. Lupus. 2021;30:2017&#x2013;2018. doi: 10.1177/09612033211033989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211033989</ArticleId><ArticleId IdType="pubmed">34284673</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:323&#x2013;331. doi: 10.1136/annrheumdis-2015-207653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207653</ArticleId><ArticleId IdType="pubmed">26338095</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, Isenberg D. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm. Phase IIb Study. Arthritis Rheumatol. 2018;70:266&#x2013;276. doi: 10.1002/art.40360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40360</ArticleId><ArticleId IdType="pmc">PMC6099253</ArticleId><ArticleId IdType="pubmed">29073347</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today (Barc) 2022;58:23&#x2013;32. doi: 10.1358/dot.2022.58.1.3352743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/dot.2022.58.1.3352743</ArticleId><ArticleId IdType="pubmed">35107091</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents. Front Med (Lausanne). 2020;7:303. doi: 10.3389/fmed.2020.00303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00303</ArticleId><ArticleId IdType="pmc">PMC7338653</ArticleId><ArticleId IdType="pubmed">32695790</ArticleId></ArticleIdList></Reference><Reference><Citation>Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol. 2015;67:1586&#x2013;1591. doi: 10.1002/art.39085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39085</ArticleId><ArticleId IdType="pubmed">25707733</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Quelhas CR, Aguirre-Alastuey ME, Isenberg DA, Saracino AM. Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018;154:1432&#x2013;1440. doi: 10.1001/jamadermatol.2018.3793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2018.3793</ArticleId><ArticleId IdType="pmc">PMC6583321</ArticleId><ArticleId IdType="pubmed">30383114</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta N, Baskaran N, Arava S, Gupta S. B cell depletion therapy using rituximab to induce long-term remission of recalcitrant skin lesions of subacute cutaneous lupus erythematosus. BMJ Case Rep. 2022 doi: 10.1136/bcr-2021-248476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-248476</ArticleId><ArticleId IdType="pmc">PMC9150159</ArticleId><ArticleId IdType="pubmed">35623653</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold J, Dass S, Twigg S, Jones CH, Rhodes B, Hewins P, et al. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. Rheumatology (Oxford) 2022;61:4905&#x2013;4909. doi: 10.1093/rheumatology/keac150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac150</ArticleId><ArticleId IdType="pubmed">35266512</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Guthridge J, Zack D, Foster P, Burington B, Tran L, et al. SAT0187 discrimination of systemic lupus (SLE) patients with clinical response to obexelimab (XMAB\textregistered5871) based on a pattern of immunologic markers. Ann Rheum Dis. 2020;79:1035&#x2013;1036. doi: 10.1136/annrheumdis-2020-eular.2972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-eular.2972</ArticleId></ArticleIdList></Reference><Reference><Citation>Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65:2368&#x2013;2379. doi: 10.1002/art.38037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38037</ArticleId><ArticleId IdType="pubmed">23740801</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Werth VP, Furie R, van Vollenhoven R, D&#xf6;rner T, Petronijevic M, et al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N Engl J Med. 2022;386:1034&#x2013;1045. doi: 10.1056/NEJMoa2106535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2106535</ArticleId><ArticleId IdType="pubmed">35294813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383:1149&#x2013;1155. doi: 10.1056/NEJMoa2023325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023325</ArticleId><ArticleId IdType="pubmed">32937047</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Cheng Q, Klotsche J, Khodadadi L, Waka A, Biesen R, et al. Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol. 2018;48:1573&#x2013;1579. doi: 10.1002/eji.201847492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847492</ArticleId><ArticleId IdType="pubmed">29979809</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnell JL, Wu Y, Mittereder N, Smith MA, Gunsior M, Yan L, et al. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. Sci Transl Med. 2021 doi: 10.1126/scitranslmed.abf8442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf8442</ArticleId><ArticleId IdType="pubmed">34039741</ArticleId></ArticleIdList></Reference><Reference><Citation>Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022;387:321&#x2013;331. doi: 10.1056/NEJMoa2118024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118024</ArticleId><ArticleId IdType="pubmed">35939578</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. Anifrolumab, an anti-interferon-&#x3b1; receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69:376&#x2013;386. doi: 10.1002/art.39962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211&#x2013;221. doi: 10.1056/NEJMoa1912196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie RA, Bruce IN, Vital EM, Dall'Era M, Maho E, et al. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatol. 2022;4:e282&#x2013;e292. doi: 10.1016/S2665-9913(21)00317-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00317-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 2022 doi: 10.1002/art.42392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42392</ArticleId><ArticleId IdType="pmc">PMC10098934</ArticleId><ArticleId IdType="pubmed">36369793</ArticleId></ArticleIdList></Reference><Reference><Citation>Tummala R, Abreu G, Pineda L, Michaels MA, Kalyani RN, Furie RA, Morand EF. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med. 2021 doi: 10.1136/lupus-2020-000464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000464</ArticleId><ArticleId IdType="pmc">PMC7893670</ArticleId><ArticleId IdType="pubmed">33597205</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum FR, Sampath AJ, Foulke GT. Anifrolumab for treatment of refractory cutaneous lupus erythematosus. Clin Exp Dermatol. 2022 doi: 10.1111/ced.15335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ced.15335</ArticleId><ArticleId IdType="pubmed">35844070</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#xfc;&#xdf; M, Piantoni S, Wincup C, Korsten P. rapid response of refractory systemic lupus erythematosus skin manifestations to anifrolumab&#x2014;a case-based review of clinical trial data suggesting a domain-based therapeutic Approach. J Clin Med. 2022 doi: 10.3390/jcm11123449.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11123449</ArticleId><ArticleId IdType="pmc">PMC9225134</ArticleId><ArticleId IdType="pubmed">35743519</ArticleId></ArticleIdList></Reference><Reference><Citation>Fetter T, Smith P, Guel T, Braegelmann C, Bieber T, Wenzel J. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions. Front Immunol. 2020;11:344. doi: 10.3389/fimmu.2020.00344.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00344</ArticleId><ArticleId IdType="pmc">PMC7064060</ArticleId><ArticleId IdType="pubmed">32194562</ArticleId></ArticleIdList></Reference><Reference><Citation>Braegelmann C, H&#xf6;lzel M, Ludbrook V, Dickson M, Turan N, Ferring-Schmitt S, et al. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. Exp Dermatol. 2016;25:375&#x2013;379. doi: 10.1111/exd.12986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/exd.12986</ArticleId><ArticleId IdType="pubmed">26910509</ArticleId></ArticleIdList></Reference><Reference><Citation>Werth VP, Fleischmann R, Robern M, Touma Z, Tiamiyu I, Gurtovaya O, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford) 2022;61:2413&#x2013;2423. doi: 10.1093/rheumatology/keab685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab685</ArticleId><ArticleId IdType="pmc">PMC9157055</ArticleId><ArticleId IdType="pubmed">34498056</ArticleId></ArticleIdList></Reference><Reference><Citation>Calugareanu A, Grolleau C, Le Buanec H, Chasset F, Jachiet M, Battistella M, et al. Clinical efficacy of selective JAK1 inhibition and transcriptome analysis of chronic discoid lupus erythematosus. J Eur Acad Dermatol Venereol. 2022;36:e308&#x2013;e310. doi: 10.1111/jdv.17839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.17839</ArticleId><ArticleId IdType="pubmed">34839559</ArticleId></ArticleIdList></Reference><Reference><Citation>Joos L, Vetterli F, Jaeger T, Cozzio A, von Kempis J, Rubbert-Roth A. Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib. Clin Exp Dermatol. 2022;47:748&#x2013;750. doi: 10.1111/ced.15005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ced.15005</ArticleId><ArticleId IdType="pubmed">34747511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuter A, Licciardi-Fernandez MJ, Burmann S-N, Paschos A, Michalowitz A-L. Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia. Clin Exp Dermatol. 2022;47:787&#x2013;788. doi: 10.1111/ced.15044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ced.15044</ArticleId><ArticleId IdType="pubmed">34856011</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Tanaka Y, Furie R, Vital E, van Vollenhoven R, Kalunian K, et al. POS0190 efficacy and safety of baricitinib in patients with systemic lupus erythematosus: results from two randomised, double-blind, placebo-controlled, parallel-group, phase 3 studies. Ann Rheum Dis. 2022;81:327&#x2013;328. doi: 10.1136/annrheumdis-2022-eular.1968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.1968</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnardeaux E, Dutz JP. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep. 2022;20:61&#x2013;64. doi: 10.1016/j.jdcr.2021.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2021.09.030</ArticleId><ArticleId IdType="pmc">PMC8792392</ArticleId><ArticleId IdType="pubmed">35118185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316&#x2013;326. doi: 10.1056/NEJMoa2109927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109927</ArticleId><ArticleId IdType="pubmed">35081280</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. LB0004 efficacy and safety of deucravacitinib, an oral, selective, allosteric tyk2 inhibitor, in patients with active systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Ann Rheum Dis. 2022;81:209. doi: 10.1136/annrheumdis-2022-eular.5020a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.5020a</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A, Erwig L, Foster K, Nevin K, Wenzel J, Worm M, et al. Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: a double-blind Phase Ib study. Exp Dermatol. 2021;30:1686&#x2013;1692. doi: 10.1111/exd.14253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/exd.14253</ArticleId><ArticleId IdType="pmc">PMC8596667</ArticleId><ArticleId IdType="pubmed">33336508</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama A, Katoh N. Subacute cutaneous lupus erythematosus successfully treated with topical delgocitinib. J Dermatol. 2022 doi: 10.1111/1346-8138.16639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1346-8138.16639</ArticleId><ArticleId IdType="pubmed">36376242</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JJ, Little AJ, Vesely MD. Treatment of cutaneous lupus with topical ruxolitinib cream. JAAD Case Rep. 2022;28:133&#x2013;135. doi: 10.1016/j.jdcr.2022.08.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2022.08.038</ArticleId><ArticleId IdType="pmc">PMC9494033</ArticleId><ArticleId IdType="pubmed">36159722</ArticleId></ArticleIdList></Reference><Reference><Citation>Borucki R, Werth VP. Emerging therapies for cutaneous lupus erythematosus. Cutis. 2020;105:276&#x2013;277. doi: 10.12788/cutis.0007.</Citation><ArticleIdList><ArticleId IdType="doi">10.12788/cutis.0007</ArticleId><ArticleId IdType="pubmed">32716989</ArticleId></ArticleIdList></Reference><Reference><Citation>Skudalski L, Shahriari N, Torre K, Santiago S, Bibb L, Kodomudi V, et al. Emerging therapeutics in the management of connective tissue disease. Part I Lupus erythematosus and Sj&#xf6;gren syndrome. J Am Acad Dermatol. 2022;87:1&#x2013;18. doi: 10.1016/j.jaad.2021.12.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2021.12.067</ArticleId><ArticleId IdType="pubmed">35202775</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprow G, Dan J, Merola JF, Werth VP. Emerging Therapies in cutaneous lupus Erythematosus. Front Med (Lausanne). 2022;9:968323. doi: 10.3389/fmed.2022.968323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.968323</ArticleId><ArticleId IdType="pmc">PMC9313535</ArticleId><ArticleId IdType="pubmed">35899214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C, Amissah-Arthur M-B, Gayed M, Brown S, Bruce IN, D'Cruz D, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 2018;57:e1&#x2013;e45. doi: 10.1093/rheumatology/kex286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex286</ArticleId><ArticleId IdType="pubmed">29029350</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>